Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis

Abstract

In the original article, there were mistakes in Table 2 as published. We collected data with reference to both the conference abstract version and the full-text published version of the TRANSCEND NHL 001 trial conducted by Abramson et al. (1, 2); in Table 2, we showed the data from the conference abstract version, which should be changed to the full-text version. The rest of the paper,